M蛋白与周围神经病变

doi:10.3969/j.issn.1006-7795.2018.03.007

摘要/Abstract

摘要： M蛋白是由单克隆浆细胞分泌的单克隆免疫球蛋白，血中含有大量的单克隆免疫球蛋白又称为副蛋白血症。临床上，副蛋白血症与周围神经病变关系密切。本文从血液学角度，总结了M蛋白相关周围神经病变的发病机制、常见临床情况、诊断以及治疗，以期加深理解、为临床诊疗提供帮助。

关键词: 单克隆免疫球蛋白, 周围神经病变, 副蛋白血症

Abstract: Monoclonal protein is produced by monoclonal plasma cells. When much monoclonal protein emerges in blood, it is named as paraproteinemia. Clinically, paraproteinemia is closely related to peripheral neuropathy (PN). This article has reviewed the pathogenesis, general disorders, diagnosis and treatment of PN in order to offer help in clinical practice.

Key words: monoclonal immune globulin protein, peripheral neuropathy, paraproteinemia

中图分类号:

R741

郝渊渊, 孙婉玲. M蛋白与周围神经病变[J]. 首都医科大学学报, 2018, 39(3): 344-348.

Hao Yuanyuan, Sun Wanling. Monoclonal protein and peripheral neuropathy[J]. Journal of Capital Medical University, 2018, 39(3): 344-348.

参考文献

[1] Katz J S, Saperstein D S, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy[J]. Neurology, 2000,83(3):615-620.
[2] Filosto M, Cotelli M, Todeschini A, et al. Clinical spectrum and evolution of monoclonal gammopathy-associated neuropathy[J]. Neurologist,2012,18(6):378-384.
[3] Nobile-Orazio E. Hand book of clinical neurology[M]. Netherlands:Elsevier, 2013:443-459.
[4] Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP:clinical, electrophysiological, laboratory features and response to treatment in 10 cases[J]. Eur J Neurol, 2011,18(6):899-905.
[5] Svahn J, Petiot P, Antoine J, et al. Anti-MAG antibodies in 202 patients:clinicopathological and therapeutic features[J]. J Neurol Neurosurg Psychiatry, 2018,89(5):499-505.
[6] Kawagashira Y, Koike H, Ohyama K, et al. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody[J]. J Neurol Sci, 2015,348(1-2):67-73.
[7] Larsen L H, Lund T, Vilholm O J, et al. Anti-myelin associated glycoprotein neuropathy responding to lenalidomide[J]. Leuk Res, 2011,35(11):e198-e199.
[8] Stino A M, Efebera Y. Lenalidomide-responsive antimyelin-associated glycoprotein neuropathy[J]. Muscle Nerve, 2017,56(4):E31-E32.
[9] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2017年修订)[J]. 中华内科杂志, 2017,56(11):866-870.
[10] D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma):a single-center experience[J]. Blood, 2012,120(1):56-62.
[11] Muchtar E, Gertz M A, Kumar S K, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014:cracking the glass ceiling of early death[J]. Blood, 2017,129(15):2111-2119.
[12] Karam C, Klein C J, Dispenzieri A, et al. Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome[J]. Neurology, 2015,84(19):1981-1987.
[13] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组, 中国抗淋巴瘤联盟. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志,2016,37(9):729-734.
[14] Treon S P, Xu L, Yang G, et al. MYD88 L265P somatic mutation in waldenstrom's macroglobulinemia[J]. N Engl J Med, 2012,367(9):826-833.
[15] Treon S P. How I treat Waldenstrom macroglobulinemia[J]. Blood, 2015,126(6):721-732.
[16] Campagnolo M, Zambello R, Nobile-Orazio E, et al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy[J]. J Neurol Neurosurg Psychiatry, 2017,88(12):1094-1097.
[17] Treon S P, Tripsas C K, Meid K, et al. Ibrutinib in previously treated waldenstrom's macroglobulinemia[J]. New Engl J Med, 2015,372(15):1430-1440.
[18] 曹欣欣, 孟琦, 蔡昊,等. 华氏巨球蛋白血症患者的临床特征、myd88l265p、cxcr4whim突变和预后:单中心93例回顾性分析[J]. 中华血液学杂志, 2017(6):494-498.
[19] Attarian S, Boucraut J, Hubert A M, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies:response to IVIg therapy[J]. J Neurol Neurosurg Psychiatry, 2010,81(1):61-64.
[20] Delmont E, Jeandel P Y, Hubert A M, et al. Successful treatment with rituximab of one patient with CANOMAD neuropathy[J]. J Neurol, 2010,257(4):655-657.
[21] Garcia-Santibanez R, Zaidman C M, Sommerville R B, et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA)[J]. J Neurol, 2018,[Epub ahead of print]
[22] Mauermann M L, Sorenson E J, Dispenzieri A, et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP[J]. J Neurol Neurosurg Psychiatry, 2012,83(5):480-486.
[23] Nasu S, Misawa S, Sekiguchi Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy[J]. J Neurol Neurosurg Psychiatry, 2012,83(5):476-479.
[24] Dispenzieri A. POEMS syndrome:2017 Update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2017,92(8):814-829.
[25] 中国医师协会血液科医师分会多发性骨髓瘤专业委员会. 多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)[J]. 中华内科杂志,2015,54(9):821-824
[26] Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017,28(suppl4):iv52-iv61.
[27] Dimopoulos M A, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR):an interim overall survival analysis of an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2017,18(10):1327-1337.
[28] Dimopoulos M, Wang M, Maisnar V, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase Ⅲ ASPIRE study[J]. J Hematol Oncol, 2018,11(1):49.
[29] Oke O, Sethi T, Goodman S, et al. Outcomes from autologous hematopoietic cell transplantation versus chemotherapy alone for the management of light chain amyloidosis[J]. Biol Blood Marrow Transplant, 2017,23(9):1473-1477.
[30] Cohen A D. A phase i dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis[J]. Blood, 2014,124(21):4741.